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PATIENTOUTCOMES BY CONDITIONING REGIMEN
Median Day 7
TNFR1 Levels (pg/mL)
Mean Day 7 TNFR1
Levels (pg/mL)
Day 100 Grade
2-4 GVHD
Day 100 Grade
3-4 GVHD
Day 100
NRM
2 year
NRM
2 year
OS
Overall (n5 96) 2518 3053 53% 23% 16% 34% 55%
FluBu4 (n5 31) 1735 1897 39% 11% 0% 12% 70%
BCNU/Busulfan (n5 36) 2552 3009 61% 25% 14% 31% 58%
TBI (n5 29) 3907 4226 62% 32% 34% 55% 38%
S158 Oral Presentationsfirst 100 days (p\0.001), and improved 2 year survival rates (70%
p5 0.03).
Our data suggest that etanercept effectively reduces TNFR1 levels
at day 7 post-HCT, which has previously been correlated with trans-
plant outcomes. The median day 7 TNFR1 levels were statistically
different across conditioning regimens, and those with low
TNFR1 levels had improved outcomes (FluBu4. BCNU/Busul-
fan.TBI). The combination of FluBu4 with etanercept as a prom-
ising regimen for high-risk allogeneic HCT warrants further
investigation.10
THE ROLE OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) IN HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED UNRE-
LATED DONORS
Ciurea, S.O.1, Cano, P.2, de Lima, M.1, Thall, P.F.3, Rondon, G.1,
Kebriaei, P.1, Alousi, A.1, Hosing, C.1, Khouri, I.F.1, Champlin, R.E.1,
Fernandez-Vina, M.2 1The University of Texas M.D. Anderson Cancer
Center; 2The University of Texas M.D. Anderson Cancer Center; 3The
University of Texas M.D. Anderson Cancer Center, Houston, TX
We have previously identified a high risk of primary graft failure
(PGF) in patients with DSA in T-cell depleted haploidentical trans-
plantation (HaploSCT); 3/4 patients with DSA developed PGF
compared with 1/20 patients without DSA. All patients with DSA
against anti-HLA-A, -B and -DRB1 developed PGF, while 1 patient
with anti-DP DSA did not. We hypothesized that anti-DP anti-
bodies may have a significant but less deleterious impact on engraft-
ment and evaluated the occurrence of PGF in 487 patients who
received matched unrelated donor transplants (MUDT) at our insti-
tution after 9/2005. Approximately 80% of the transplants were mis-
matched in HLA-DPB1 in the HvG vector. The presence of DSA
was determined by testing the patients’ sera with a panel of fluores-
cent beads coated with single HLA antigen preparations using
a Luminex platform; results were interpreted as fluorescence
intensity (FI) against DSA mismatch as previously defined by us
(see Table Footer). HLA-A,-B,-C,-DRB1,-DRB3/4/5,-DQB1 and
-DPB1 were typed by high resolution methods. Specificity and
intensity of antibodies is described in the Table. Eight patients had
PGF, and 8 had early death. In each category one had DSA. Median
time to ANC500 was 12 days. We found that 5 patients (1%)
presented DSA in their pre-transplant specimens, all females with
a median age of 49 years, and matched with their donors in 10/10 al-
leles. In all patients the DSA were directed against HLA-DP mole-
cules with intermediate to strong intensities. One patient withNumber Anti-DP DSA
DSA
levels
before
1st SCT
Engrafted
(Y/N)
2nd
SCT
(Y/N)
DSA
levels
before
2nd SCT
Engrafted
(Y/N)
1 DPB1*03DBZB 41 N N N/A N/A
2 DPB1*0401 11 to 21 Y N N/A N/A
3 DPB1*0301 31 N Y 0 Y
4 DPA1*0201
and DPB1*0101
31 Y N N/A N/A
5 DPB1*0101 and
DPB1*1101
31 and 11 Y N N/A N/A
DSA-donor-specific anti-HLA antibodies; Y- yes, N-no; N/A- not applica-
ble; 0 - no DSA, FI\500 or negative; weak (500-1500 FI, 11), interme-
diate (1500-3000 FI, 21), strong (3000-7500 FI, 31); very strong
(.7500 FI, 41).DSA (#1) received rituximab/plasma exchange prior to transplant
to decrease DSA levels and died on day 22 without engraftment. Ex-
cluding the patients with early death, we have found a moderate as-
sociation between anti-DP antibodies and PGF (p5 0.0654). When
early death was considered as a negative event associated with DSA,
a significant association was identified between the presence of anti-
DP DSA and graft failure/early death outcome (p5 0.0108, Fisher’s
Exact Test).
Conclusions:These results, combined with our previous findings in
HaploSCT, suggest that anti-DP DSA compared with DSA against
anti-HLA-A, B or DRB1 may have a lower risk for PGF. The differ-
ences may reside in the lower levels of DP molecules expressed on
cell surface. DSA screening is warranted when considering donors
with HLA mismatches as strategies for donor selection and/or anti-
body level reduction may be needed to decrease the risk of PGF in
allogeneic HSCT from partially HLA-matched donors.11
EVALUATION OF PATIENTSWITH MYELODYSPLASTIC SYNDROME (MDS)
UP TO AGE SEVENTY-FIVE, REFERRED FOR ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANT (HCT) INCLUDING DONOR AVAILABILITY AND
HCT OUTCOMES
Field, T.L., Perkins, J., Kim, J., Kharfan-Dabaja,M.A., Fenandez, H.F.,
Perez, L., Lancet, J., Komrokji, R.S., Ochoa-Bayona, L., Alsina, M.,
List, A., Anasetti, C. Moffitt Cancer Center, Tampa, FL
Allogeneic HCT remains the only curative treatment strategy for
patients (pts) with MDS. Moffitt Cancer Center (MCC) has imple-
mented a targeted IV busulfan plus fludarabine (tBuFlu) induction
regimen that is myeloablative, with reduced treatment related toxic-
ity, permitting the expansion of empiric age limitations for HCT up
to 75 years (yrs). From January 2004 on, 243 new pts (NP) with a
diagnosis of MDS or CMML were evaluated for HCT. An alloge-
neic donor was identified in 170 pts and 112 received an HCT.
The median age of the 112 transplant pts was 55.6 yrs (24.8 –
73.5). Sixty pts were older than 55 yrs. At the NP visit, IPSS risk
was Low (11), Int-1 (35), Int-2 (42), and High (21) or not evaluable
(3) (NE). Donors included 49 sibling donors (SIB), 48 matched
unrelated donors (MUD) and 15 mismatched unrelated donors
(mMUD). Median follow-up is 19.3 months (0 – 61.4) and the
Kaplan-Meier overall survival (OS) from NP visit is 77% at one
year and 56% at two years. Overall survival is not statistically differ-
ent between SIB, MUD or mMUD HCT (P5 0.39). In 58 pts who
did not receive a HCT, a donor was identified. (Yes donor, No
HCT) Median age was 57 yrs (19 – 69) with 28 pts older than
55yrs. At the NP visit, IPSS was Low (5), Int-1 (19), Int-2 (17),
High (16) and NE (1). Donors included SIB (14), MUD (27),
mMUD (15), and umbilical cord blood (2). Median follow up is
10.3 months (1.7 – 66.3). Seventy-three pts did not obtain a donor
(No Donor, No HCT). Median age was 64.4 yrs (32.6 – 72.1)
with 65 pts older than 55yrs. IPSS at NP visit was Low (8), Int-1
(16), Int-2 (25), High (16) and NE (8). Median follow up of these
pts is 6.7 months (0.9 – 61.3). For the entire cohort (243 pts), pts
with a donor had significantly improved overall survival vs pts with
no donor (P5 0.003); there was no difference in OS between pts
with a donor who did not proceed to HCT and everyone without
a donor (P5 0.27). Twenty-eight of the 73 pts without a donor
did not have donor searches. If these are excluded, in the remaining
215pts OS for pts with an identified donor was improved compared
to OS of those without a donor (P5 0.009) and pts with a donor and
no HCT had similar OS to those without an identified donor
(P5 0.3). These data demonstrate that 70% of patients can acquire
a suitable allogeneic donor and 47% of patients seen as a HCT new
Oral Presentations S159patient consult can proceed to HCT for MDS with a significant
overall survival advantage using a SIB, MUD or mMUD.12
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MAJOR THALAS-
SEMIA: NINETEEN YEARS EXPERIENCE IN IRAN
Ghavamzadeh, A., Alimoghaddam, K., Jahani, M., Hamidieh, A.A.,
Mousavi, S.A., Khatami, F., Jalali, A., Alimohammadi, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Objective:Hematopoietic Stem Cell Transplantation (HSCT) still
remains the only cure available for Major Thalassemia. Below there
are the results of 19 years using HSCT as treatment in our centre.
Patients and Methods: 425 Major Thalassemia Patients, (242 male
and 183 female) with a median age of 7 (Range: 2-28 years), have re-
ceived HSCT from July 1991 through October, 2009. From 425 pa-
tients, 113 patients were in class I, 146 in class II, 142 in class III and
24 inThalassemia Intermediate. They received allogeneic transplanta-
tion from 407 HLA full matched siblings, nine HLA mismatched sib-
lings or other relatives, nine HLA full matched other relatives. The
sources of HSCT were 158 bone marrow, 194 peripheral blood, 9
cord blood and one bone marrow combined with peripheral blood.
Since three years ago 58 patients with class III thalassemia were ran-
domized for double blind study with two groups; one with co-trans-
plantation (mesenchymalcells) andanotherwithoutmesenchymalcells.
Results:Themedian time toAbsoluteNeutrophilCount$0.5 109/
L and platelet count $20 109/L were +15 and +22, respectively.
Acute GvHD occurred in 281 (66%) and chronic GvHD in 91
(21.4%) patients. 356 (83.8%) patients are still living and 69 (16.2%)
are deceased. The most common cause of death was GvHD. 5-year
overall survival (OS) and disease-free survival (DFS) were 79.8% and
70.2%, respectively. The 5-year OS of patients with peripheral blood
and bone marrow stem cell were 75.5% and 84.2%, respectively
(p5 .141). The 5-year DFS of peripheral blood and bone marrow
recipients were 69.3% and 73.1%, respectively (p5 .773). Up to now
the results ofHSCT for both groups in double blind randomized study
is same and we have to wait for future analysis.
Conclusion: HSCT, based on our experience and other docu-
mented studies, is an acceptable treatment for Major Thalassemia
with better results in younger patients.
KEY WORDS Hematopoietic Stem Cell Transplantation, Major
Thalassemia13
IL-15 ENHANCES IN-VITRO EXPANSION AND FUNCTIONAL ACTIVITY OF
ANTIGEN-SPECIFIC EFFECTOR MEMORY T CELLS (TEM) WHILE CO-
EXPRESSION OF IL-15 AND IL-15 R ON ANTIGEN PRESENTING CELLS
ALSO PROMOTES ENRICHMENT AND PREFERENTIAL EXPANSION OF
CENTRAL MEMORY T-CELLS (TCM)
Hasan, A.N.1, Selvakumar, A.1,2, Liu, X.-R.2, Sadelain, M.W.3,
Riviere, I.3, Dupont, B.2, O’Reilly, R.J.1,2 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Sloan-Kettering Institute, New York,
NY; 3Memorial Sloan-Kettering Cancer Center, New York, NY
Adoptive immunotherapy with in-vitro expanded antigen-specific
T cells (TC) is often hampered by extended culture times and limited
persistence of infused cells in-vivo. IL-2 predominantly supports the
generation of short-lived effector memory (TEM) and effector (TE)
CD8+ TCwithout expanding the CD62L+ andCCR7+ central mem-
ory TC (TCM), which may persist longer in- vivo. We examined if
IL-15 could foster the growth of CMVpp65-specific TEM and
TCM CD8
+ TC.
TC from 6 HLA-A0201+ seropositive donors were sensitized in-
vitro using HLA-A0201+, CMVpp65+ artificial antigen presenting
cells (Hasan et al. JI, 2009) (A2-AAPC). To assess if trans-presenta-
tion of IL-15 on AAPCs leads to enhanced IL-15 activity, we sequen-
tially transduced A2-AAPCs with the IL-15 and IL-15 Ra cDNA
(A2-AAPCIL-15/IL-15Ra). TC were cultured using A2-AAPC with (i)
IL-2 (20U/ml) (ii) IL-15 (10ng/ml) (iii) IL-2 plus IL-15 or (iv)
A2-AAPCIL-15Ra + IL-2 (20U/ml) (v) A2-AAPCIL-15Ra + IL-15
(10ng/ml) or (vi) A2-AAPCIL-15/IL-15Ra
Starting from a precursor frequency of 0.5-2 x 104/5 million TC,
cultures supplemented with IL-15 demonstrated upto 2000 foldexpansion of CMVpp65 tetramer (+)TC and generated 25-70 x106
A2-NLV tetramer (+) CD8+ TC, compared to a 300-600 fold expan-
sion and 6-12 x106 tetramer (+) CD8+ TCwith IL-2 after 21-28 days.
Sensitization with A2-AAPCIL-15/IL-15Ra exhibited rapid and signif-
icant enrichment of CMVpp65 A2-NLV tetramer (+) CD8+ TC
between day 14-28. There were no TCM detected by 21 days among
tetramer (+) TC in cultures (i) to (v). However, TC sensitized with
A2-AAPCIL-15/IL-15Ra contained 12-15% (7106) tetramer (+)
CD8+ TCM which further increased through day 35. In functional
assays, sensitization with A2-AAPCIL-15/IL-15Ra generated 35-53%
CD8+ CMVpp65 epitope-specific IFNg+ TC compared to 11-26%
in cultures with exogenous IL-15 and 2-10% in cultures with IL-2.
Cytotoxic activity was also higher for TC sensitized with A2-AAP-
CIL-15/IL-15Ra (80-90%) compared to cultures with IL-2 (60%).
These data demonstrate that any condition using IL-15 generates
higher yields of antigen-specific TC. However, TC cultures supple-
mented with IL-15 +/- IL-2 only supported sustained expansion of
TEM and TE. In contrast, TC sensitized with A2-AAPC
IL-15/IL-15Ra
also supported sustained expansion of TCM with augmented
functional activity. Therefore AAPCIL-15/IL-15Ra presents a novel
practical approach for expansion of antigen-specific TCM for adop-
tive immunotherapy.
Differential Expansion and Function of CMVpp65-specific
Memory T-cells
Fold Fold ExpansionCulture
ConditionExpansion
Tet [1]
CD8 TCTet [1]
CD62L
[1]CD8 TC% CD8
IFN
g [1] TC
%
CytotoxicityA2-AAPC1 IL-2 200-600 60-90 2-10 28-60
A2-AAPC1 IL-15 300-1300 11-82 10-18 60-75
A2-AAPC
1 IL-21 IL-15250-700 25-150 8-20 40-72A2-AAPCIL-15Ra
1 IL-2
25-100 4-10 2-7 30-45A2-AAPCIL-15Ra
1 IL-15
100-300 20-50 11-20 60-75A2-AAPCIL-15/IL-15Ra 1200-2300 400-1007 35-53 80-9514
IN VITRO INDUCTION OF ADENOVIRUS SPECIFIC T-CELLS IN RESPONSE
TO 15-MER PEPTIDES IN UMBILICAL CORD BLOOD
Haveman, L.M.1,2, Bulatovic, M.1,2, Meerding, J.M.2, Prakken, B.1,2,
Bierings, M.1 1University Medical Center Utrecht, Wilhelmina Child-
ren’s Hospital, Utrecht, Netherlands; 2UniversityMedical Center Utrecht,
Wilhelmina Children’s Hospital, Utrecht, Netherlands
Human adenovirus (HAdV) infections are a serious life-threat in
hematopoietic stem cell transplantation patients, particularly in chil-
dren. In recent years, umbilical cord blood (UCB) transplants
emerged as an alternative stem cell source. However, the immune
reconstitution is severely hampered in CBT recipients leading to
higher risk of viral infections. Because no effective antiviral medica-
tion exist for severe HAdV infection, replenishing HAdV-specific
immunity through adoptive transfer of HAdV-specific T-cells could
be a promising treatment.
Aim of this study was to induce HAdV-specific T-cells with low
contamination of residual potentially alloreactive T-cells from
UCB. Therefore, cord blood mononuclear cells (CBMCs) were cul-
tured with 5 previously described pan-DR binding 15-mer HAdV
peptides derived from HAdV serotype 5.1 To examine if the mainly
antigen naive UCB T-cells were able to recognize the different
HAdV-peptides, CBMCs of 34 deliveries were cultured with the
HAdV peptides for 5 days without adding supplemental cytokines.
CBMCs of 17 cord blood samples (5 50%) showed a proliferative
response to 43 of the various HAdV-peptides or to the pool of the
peptides, with a stimulation index ranging from 1.7 to 19.1 as deter-
mined by 3H-thymidine proliferation assay. To induce HAdV spe-
cific T-cells, CBMCs derived from 19 deliveries were subsequently
cultured for 7 dayswith theHAdVpeptides or a pool of these peptides
after adding of 40 IU/ml IL2. Compared with medium stimulated
cells HAdV-specific T-cells expressed significantly (p\0.05) more
of the activation markers CD25 and CD69 and harbor a memory
